Directorio

We are doing this study to look at blood, tumor, and lymph node tissue from people with melanoma so we can improve diagnostic methods and therapies for people with melanoma.

We are doing this study to learn more about the symptoms of menopause in women with sickle cell disease (SCD). We want to learn more about how hydroxyurea, pain, and other SCD-related complications can affect their menopause experience. We hope this study can help us more quickly and easily find out when women with SCD might be experiencing health complications related to menopause.

We are doing this study to find the most effective, safe dose of an experimental drug called bomedemstat (the study drug) for people with essential thrombocythemia who are unable to take hydroxyurea or do not get a benefit from it.

We are doing this study to find the most effective, safe dose of an experimental drug called petosemtamab (the study drug). We also want to know how well it works compared to the standard treatments used for metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

We are doing this study to identify new signs and symptoms of inflammatory bowel disease (IBD) in children and young adults. We want to improve at predicting the future course of IBD so that we can treat it better and faster. We also hope this study will help us learn how IBD develops so that we can make new treatments for IBD.

We are doing this study to learn more about how well a study intervention works to reduce distress caused by misophonia. This intervention combines neurostimulation and skills-based training that is designed to help people think differently.

We are doing this study to find the most effective, safe dose of an experimental drug called bomedemstat or hydroxyurea in people with essential thrombocythemia (ET). We also want to know which of these options works best for most people.

We are doing this study to find out if adding a drug called enasidenib (the study drug) to the standard treatment for myelodysplastic syndrome (MDS) can improve the likelihood of achieving complete remission. The study drug is approved for acute myeloid leukemia (AML), but is not approved for the treatment of MDS.